TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10216104

Group type: EXPERIMENTAL
Intervention: FLT3 gene mutation
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: N-RAS gene mutation
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Age 60 years or older
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Cytogenetic data
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: FAB types other than M2
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Leukocytosis over 100 +/- 10(9)/L
Number of subjects: 201
Study: 7618972

Group type: EXPERIMENTAL
Intervention: Early oral feeding (clear liquid diet on the first postoperative day followed by a regular diet as tolerated)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Regular feeding (traditional method, feeding only after resolution of postoperative ileus)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Early oral feeding
Number of subjects: 161
Study: 2613390

Group type: EXPERIMENTAL
Intervention: Vadocaine hydrochloride tablet (30 mg t.i.d. for four days)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Vadocaine hydrochloride solution
Number of subjects: 28
Study: 796755

Group type: EXPERIMENTAL
Intervention: 600 mg chlorpromazine/day
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: 300 mg chlorpromazine/day
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: 300 mg chlorpromazine‐‐250 mg alpha‐methyldopa/day
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: 300 mg chlorpromazine‐‐500 mg alpha‐methyldopa/day
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: 300 mg chlorpromazine‐‐750 mg alpha‐methyldopa/day
Number of subjects: 55
Study: 31234240

Group type: EXPERIMENTAL
Intervention: Valbenazine (low dose: 40 or 50 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Valbenazine (high dose: 75 or 80 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27274016

Group type: EXPERIMENTAL
Intervention: Electronic notes
Number of subjects: 21
Study: 26787182

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (Exacyl, 1.5 g i.v.) before the operation
Number of subjects: 119

Group type: COMPARATOR
Intervention: Control group (no antifibrinolytic agent)
Number of subjects: 119
Study: 23340963

Group type: EXPERIMENTAL
Intervention: Insoluble yeast (1,3)-(1,6)-beta-D-glucan preparation (900 mg per day for 16 weeks)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Insoluble yeast (1,3)-(1,6)-beta-D-glucan preparation
Number of subjects: 162

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study: 21697059

Group type: EXPERIMENTAL
Intervention: Intramuscular methotrexate
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: PUVA treatment (3 times/week for ten weeks)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 24
Study: 18268496

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (100 mg every other day)
Number of subjects: 0
Study: 16716319

Group type: EXPERIMENTAL
Intervention: Laser-assisted intracytoplasmic sperm injection (ICSI)
Number of subjects: 0
Study: 12920491

Group type: EXPERIMENTAL
Intervention: Quinine hydrochloride (500 mg) alone
Number of subjects: 9

Group type: COMPARATOR
Intervention: Ketoconazole (100 mg twice daily for 3 days)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Fluvoxamine (25 mg twice daily for 2 days)
Number of subjects: 9
Study: 10867536

Group type: EXPERIMENTAL
Intervention: 5 mg folic acid daily for 3 months
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 21
Study: 9446076

Group type: EXPERIMENTAL
Intervention: Methoxibutropate (1200 mg/day for 20 days)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nimesulide (200 mg/day)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Methoxibutropate
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nimesulide
Number of subjects: 60
Study: 1287905

Group type: EXPERIMENTAL
Intervention: Intravenous artesunate
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Intramuscular artesunate
Number of subjects: 28
Study: 3701184

Group type: EXPERIMENTAL
Intervention: Synthetic culture medium (B3 INRA Menezo)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Serum (heat-inactivated patient serum)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-percentage or 100% patient serum for embryo replacement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Synthetic medium with bovine serum albumin (B2 INRA Menezo)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: B3 medium
Number of subjects: 0
Study: 29570108

Group type: EXPERIMENTAL
Intervention: Lidocaine (1.5 mg/kg intravenous lidocaine over 5 min followed by 2 mg/kg/h)
Number of subjects: 92

Group type: COMPARATOR
Intervention: 0.9% saline (at the same rate and volume as lidocaine)
Number of subjects: 92
Study: 26821712

Group type: EXPERIMENTAL
Intervention: Religiously-tailored HIV education and testing materials/activities delivered by church leaders (e.g., sermons, brochures/bulletins, testimonials)
Number of subjects: 543

Group type: COMPARATOR
Intervention: Control group (comparison group)
Number of subjects: 543
Study: 24309381

Group type: EXPERIMENTAL
Intervention: Care-seeking intervention (CSI)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Attention control group (life review interviews)
Number of subjects: 90
Study: 22958024

Group type: EXPERIMENTAL
Intervention: Extra-protein group (4.8 g kg(‐1) per day)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control group (3.5 g kg(‐1) per day)
Number of subjects: 2
Study: 20562496

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 40
Study: 18543317

Group type: EXPERIMENTAL
Intervention: Standardized HRQL assessments via touch-screen computer
Number of subjects: 219
Study: 15693916

Group type: EXPERIMENTAL
Intervention: mMMDT 80 mg/kg/day
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: mMMDT 40 mg/kg/day
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 12660886

Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Felodipin
Number of subjects: 42
Study: 10418398

Group type: EXPERIMENTAL
Intervention: Strength training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 7672685

Group type: EXPERIMENTAL
Intervention: IBD patients
Number of subjects: 152

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Lifetime corticosteroid dose > 10 g
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Never taken peroral corticosteroids
Number of subjects: 152
Study: 2122007

Group type: EXPERIMENTAL
Intervention: Neoadjuvant methotrexate, cisplatin and vinblastine chemotherapy plus 2 additional courses of cisplatin and 4,000 cGy irradiation.
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Full chemotherapy and radiotherapy (including a radiotherapy boost to a total of 6,480 cGy plus 1 additional course of cisplatin).
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Immediate radical cystectomy due to positive biopsy and/or cytology results after 4,000 cGy.
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with dose reductions due to stomatitis, bone marrow depression, and/or renal dysfunction.
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Overall treatment efficacy and tolerability.
Number of subjects: 53
Study: 6900141

Group type: EXPERIMENTAL
Intervention: 10‐session comprehensive psychosocial smoking prevention program
Number of subjects: 281

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 281
Study: 31563397

Group type: EXPERIMENTAL
Intervention: 10 mg dexamethasone IV 1 hour before surgery
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg dexamethasone IV 24 hours after surgery
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg dexamethasone IV 24 hours after surgery
Number of subjects: 44

Group type: COMPARATOR
Intervention: Normal saline injection (control group)
Number of subjects: 44
Study: 31399108

Group type: EXPERIMENTAL
Intervention: 8 Gy irradiated T lymphocytes from patients with grade ≥ 2 bf+
Number of subjects: 2

Group type: COMPARATOR
Intervention: 8 Gy irradiated T lymphocytes from patients with grade < 2 bf+
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Peripheral blood mononuclear cells from patients with grade ≥ 2 bf+
Number of subjects: 2

Group type: COMPARATOR
Intervention: Peripheral blood mononuclear cells from patients with grade < 2 bf+
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: NADPH oxidases (NOXs) analysis in both patient groups after irradiation
Number of subjects: 2
Study: 30206195

Group type: EXPERIMENTAL
Intervention: ACT-based stress management program (twice a week for four weeks)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 44
Study: 26797427

Group type: EXPERIMENTAL
Intervention: 500μg intra-arterial nitroglycerin
Number of subjects: 539

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 539
Study: 24030238

Group type: EXPERIMENTAL
Intervention: Multicomponent exercise program (twice-weekly for 12 weeks, including muscle power training at 40-60% of one-repetition maximum, balance and gait retraining)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 24
Study: 22565589

Group type: EXPERIMENTAL
Intervention: Weight based, higher-dose (HD) enoxaparin 0.5 mg/kg QDay, n = 11
Number of subjects: 31

Group type: COMPARATOR
Intervention: Weight based, lower-dose (LD) enoxaparin 0.4 mg/kg QDay, n = 9
Number of subjects: 31

Group type: COMPARATOR
Intervention: Fixed-dose (FD) enoxaparin 40 mg daily, n = 11
Number of subjects: 31
Study: 19304859

Group type: EXPERIMENTAL
Intervention: DMT
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: S-ketamine
Number of subjects: 14
Study: 17436778

Group type: EXPERIMENTAL
Intervention: Creatine (Cr) 20 g/day for 7 days
Number of subjects: 35

Group type: COMPARATOR
Intervention: Taurine (as placebo)
Number of subjects: 35
Study: 16336758

Group type: EXPERIMENTAL
Intervention: Educational leaflet
Number of subjects: 216

Group type: COMPARATOR
Intervention: No educational leaflet (Control)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Overall recurrence rate
Number of subjects: 216
Study: 11882226

Group type: EXPERIMENTAL
Intervention: Prilocaine (3 mg/kg)
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Lidocaine (3 mg/kg)
Number of subjects: 279

Group type: COMPARATOR
Intervention: Completely displaced fractures
Number of subjects: 279
Study: 9496204

Group type: EXPERIMENTAL
Intervention: Propofol-low-dose fentanyl-nitrous oxide-vecuronium, tracheal extubation immediately after surgery (group Ia)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Fentanyl-midazolam-pancuronium, delayed tracheal extubation in the ICU (group Ib)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Fentanyl-midazolam-pancuronium anaesthesia (group II)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: All groups during one-lung ventilation (OLV)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Pneumonectomy group
Number of subjects: 45
Study: 7934984

Group type: EXPERIMENTAL
Intervention: Lipid infusion
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 10
Study: 3128670

Group type: EXPERIMENTAL
Intervention: Mitomycin C (MMC) followed by HCFU for more than 3 months (group B)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Mitomycin C alone (group A)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Mitomycin C followed by HCFU (group B)
Number of subjects: 173
Study: 30130811

Group type: EXPERIMENTAL
Intervention: Instrument-assisted soft tissue mobilization
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 26549220

Group type: EXPERIMENTAL
Intervention: Foraminal Enlargement (FE) with working length of 0.0 mm from the apex
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group with working length of 1.0 mm short of the apex
Number of subjects: 46
Study: 24991038

Group type: EXPERIMENTAL
Intervention: Patients with ALS
Number of subjects: 26

Group type: COMPARATOR
Intervention: Healthy seniors (control group)
Number of subjects: 26
Study: 22884050

Group type: EXPERIMENTAL
Intervention: Gastrojejunal loop anastomosis bypass
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gastrojejunal Roux-en-Y bypass
Number of subjects: 0
Study: 20008454

Group type: EXPERIMENTAL
Intervention: Multicomponent strawberry aroma (test product)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Single-component strawberry aroma (placebo product)
Number of subjects: 41
Study: 19192857

Group type: EXPERIMENTAL
Intervention: Contingent intervention (n=10) with voucher-based incentives for smoking abstinence
Number of subjects: 20

Group type: COMPARATOR
Intervention: Noncontingent intervention (n=10) earning vouchers independent of smoking status
Number of subjects: 20
Study: 15791099

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 102

Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 102
Study: 14707789

Group type: EXPERIMENTAL
Intervention: Intensification of standard antiretroviral therapy with abacavir, with or without efavirenz.
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (standard combination antiretroviral therapy with either 3 or 4 agents).
Number of subjects: 10
Study: 10862645

Group type: EXPERIMENTAL
Intervention: Gradual prednisone reduction to zero over 6 months (Group A)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Triple-drug therapy without change (Group B)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Gradual prednisone reduction to zero (Group A)
Number of subjects: 88
Study: 9357886

Group type: EXPERIMENTAL
Intervention: BIS-titrated desflurane or sevoflurane
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control groups (standard clinical practice)
Number of subjects: 60
Study: 8418174

Group type: EXPERIMENTAL
Intervention: Treatment for Chlamydia-positive NGU
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Treatment for gonorrhea
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Chlamydia-positive NGU after cessation of therapy
Number of subjects: 67

Group type: COMPARATOR
Intervention: Chlamydia-negative NGU or persistent urethritis
Number of subjects: 67
Study: 3805326

Group type: COMPARATOR
Intervention: Amitriptyline (AT) alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Perphenazine (PER) alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amitriptyline (AT) + Perphenazine (PER)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Perphenazine (PER)
Number of subjects: 0
Study: 3396363

Group type: EXPERIMENTAL
Intervention: Low fat diet intervention (12,800 participants)
Number of subjects: 32000

Group type: COMPARATOR
Intervention: Control group (19,200 participants)
Number of subjects: 32000
Study: 31552872

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Tramadol
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Neostigmine
Number of subjects: 96
Study: 28993821

Group type: EXPERIMENTAL
Intervention: Herbal toothpaste
Number of subjects: 76

Group type: COMPARATOR
Intervention: Triclosan/copolymer toothpaste
Number of subjects: 76

Group type: COMPARATOR
Intervention: Amine/stannous fluoride toothpaste
Number of subjects: 76
Study: 25641591

Group type: EXPERIMENTAL
Intervention: Stretch-and-flow voice therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vocal hygiene education only (Control)
Number of subjects: 0
Study: 23700201

Group type: EXPERIMENTAL
Intervention: Preoperative consumption of potatoes (Group P)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 44
Study: 21815850

Group type: EXPERIMENTAL
Intervention: Gerotranscendence support group (once a week for eight weeks for 60 min)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 76
Study: 19454032

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.2 to 0.7 microg/kg/hr (with or without loading doses of 1 microg/kg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Haloperidol 0.5 to 2 mg/hour (with or without loading doses of 2.5 mg)
Number of subjects: 20
Study: 16736128

Group type: EXPERIMENTAL
Intervention: Glucose concentrations of 8.3 mmol/l
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Glucose concentrations of 11.1 mmol/l
Number of subjects: 9

Group type: COMPARATOR
Intervention: Co-infusion of insulin
Number of subjects: 9

Group type: COMPARATOR
Intervention: Somatostatin infusion
Number of subjects: 9
Study: 15001601

Group type: EXPERIMENTAL
Intervention: Fluvastatin XL (80 mg), once-daily for 8 weeks
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo, once-daily for 8 weeks
Number of subjects: 89
Study: 11376905

Group type: EXPERIMENTAL
Intervention: Muscle pain induced by hypertonic saline
Number of subjects: 0
Study: 9433583

Group type: EXPERIMENTAL
Intervention: Descriptive analysis of quantitative traits Q1-Q5
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Segregation and linkage analyses of traits Q1-Q3
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Haseman-Elston sib-pair analysis
Number of subjects: 199
Study: 8070050

Group type: EXPERIMENTAL
Intervention: Low skin impedance points (LSIP) measurement along the Lung, Pericardium, and Heart meridians
Number of subjects: 12
Study: 3101484

Group type: EXPERIMENTAL
Intervention: Five-day penicillin V potassium therapy (250 mg three times daily)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Ten-day penicillin V potassium therapy (250 mg three times daily)
Number of subjects: 172
Study: 28831554

Group type: EXPERIMENTAL
Intervention: Patient-specific instrumentation (PSI)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Conventional instrumentation (Control)
Number of subjects: 43
Study: 27473842

Group type: EXPERIMENTAL
Intervention: Positive psychology family intervention emphasizing joy, gratitude, flow, savoring, and listening.
Number of subjects: 2070

Group type: COMPARATOR
Intervention: Control group activities (arts and crafts workshops).
Number of subjects: 2070

Group type: EXPERIMENTAL
Intervention: Booster session.
Number of subjects: 2070
Study: 24928848

Group type: EXPERIMENTAL
Intervention: FIFA 11+ programme adherence
Number of subjects: 287
Study: 23952100

Group type: EXPERIMENTAL
Intervention: Disclosure of serial echocardiogram findings
Number of subjects: 88

Group type: COMPARATOR
Intervention: Nondisclosure of serial echocardiogram findings
Number of subjects: 88
Study: 20485002

Group type: EXPERIMENTAL
Intervention: Oxidized regenerated cellulose reinforcement
Number of subjects: 108

Group type: COMPARATOR
Intervention: No reinforcement (Control)
Number of subjects: 108
Study: 18091007

Group type: COMPARATOR
Intervention: Standard public health recommendation for PA (SR)
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Breast cancer-specific PA print materials (PM)
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Step pedometer (PED)
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Combination of print materials and pedometer (COM)
Number of subjects: 377
Study: 16650095

Group type: EXPERIMENTAL
Intervention: Regular teaching protocol regarding all aspects of primary prevention
Number of subjects: 521

Group type: COMPARATOR
Intervention: Control group without any further teaching
Number of subjects: 521
Study: 12511172

Group type: EXPERIMENTAL
Intervention: 1-Hz rTMS
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 24
Study: 10546469

Group type: EXPERIMENTAL
Intervention: Salmeterol (50 micrograms b.i.d. with Diskhaler, n = 66)
Number of subjects: 138
Study: 8934086

Group type: EXPERIMENTAL
Intervention: Two-pass PEG placement (39 patients)
Number of subjects: 80

Group type: COMPARATOR
Intervention: One-pass PEG placement (41 patients)
Number of subjects: 80
Study: 1748145

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 22

Group type: COMPARATOR
Intervention: Glibenclamide
Number of subjects: 22
Study: 7075639

Group type: EXPERIMENTAL
Intervention: Ro 11-2465 1 mg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Ro 11-2465 2 mg
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 31876118

Group type: EXPERIMENTAL
Intervention: nano-hydrogel embedded with quercetin and oleic acid
Number of subjects: 56

Group type: COMPARATOR
Intervention: hyaluronic acid (0.2%)
Number of subjects: 56
Study: 29935939

Group type: EXPERIMENTAL
Intervention: Acute ∆9‐THC administration
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Acute ∆9‐THC administration in non‐users
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Placebo in cannabis users
Number of subjects: 24
Study: 26909743

Group type: EXPERIMENTAL
Intervention: Curcuminoids (294 mg per day as micelles)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 25057209

Group type: EXPERIMENTAL
Intervention: Dendritic spines in adult human neocortex
Number of subjects: 500
Study: 23379240

Group type: EXPERIMENTAL
Intervention: Afala, 2 tablets 4 times a day for 6 months
Number of subjects: 94
Study: 20702792

Group type: EXPERIMENTAL
Intervention: Prior cardiovascular disease (CVD)
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Prior CVD, hypercholesterolemia, hypertension
Number of subjects: 292

Group type: COMPARATOR
Intervention: Conventional HAD risk factors and CNS penetration effectiveness rank of antiretroviral regimens
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Neurocognitive impairment
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: QNPZ-5 score
Number of subjects: 292
Study: 18359717

Group type: EXPERIMENTAL
Intervention: Inhalation of nebulized budesonide suspension plus salbutamol and ipratropium bromide twice daily for 5 days (Group A)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Dexamethasone plus aminophylline injection once daily for 5 days (Group C)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Budesonide plus salbutamol and ipratropium aerosol (Group B)
Number of subjects: 113
Study: 16242948

Group type: EXPERIMENTAL
Intervention: Aerosolized iloprost (25 microg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 22
Study: 11855542

Group type: EXPERIMENTAL
Intervention: Rebamipide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0